292 related articles for article (PubMed ID: 28461179)
1. Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
Baas W; Gershburg S; Dynda D; Delfino K; Robinson K; Nie D; Yearley JH; Alanee S
Clin Genitourin Cancer; 2017 Oct; 15(5):577-581. PubMed ID: 28461179
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
3. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Vicier C; Ravi P; Kwak L; Werner L; Huang Y; Evan C; Loda M; Hamid AA; Sweeney CJ
Prostate; 2021 Jan; 81(1):50-57. PubMed ID: 32986884
[TBL] [Abstract][Full Text] [Related]
4. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
5. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
Sharma M; Yang Z; Miyamoto H
Medicine (Baltimore); 2019 Sep; 98(38):e17257. PubMed ID: 31567999
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 Expression and CD8
Petitprez F; Fossati N; Vano Y; Freschi M; Becht E; Lucianò R; Calderaro J; Guédet T; Lacroix L; Rancoita PMV; Montorsi F; Fridman WH; Sautès-Fridman C; Briganti A; Doglioni C; Bellone M
Eur Urol Focus; 2019 Mar; 5(2):192-196. PubMed ID: 28753812
[TBL] [Abstract][Full Text] [Related]
9. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
Soo RA; Kim HR; Asuncion BR; Fazreen Z; Omar MFM; Herrera MC; Yun Lim JS; Sia G; Soong R; Cho BC
Lung Cancer; 2017 Mar; 105():17-22. PubMed ID: 28236980
[TBL] [Abstract][Full Text] [Related]
10. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
12. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
14. Functional CD3
Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
[No Abstract] [Full Text] [Related]
16. Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis.
Hahn E; Liu SK; Vesprini D; Xu B; Downes MR
J Clin Pathol; 2018 Nov; 71(11):1023-1027. PubMed ID: 30257853
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.
Haffner MC; Guner G; Taheri D; Netto GJ; Palsgrove DN; Zheng Q; Guedes LB; Kim K; Tsai H; Esopi DM; Lotan TL; Sharma R; Meeker AK; Chinnaiyan AM; Nelson WG; Yegnasubramanian S; Luo J; Mehra R; Antonarakis ES; Drake CG; De Marzo AM
Am J Pathol; 2018 Jun; 188(6):1478-1485. PubMed ID: 29577933
[TBL] [Abstract][Full Text] [Related]
18. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.
Massari F; Ciccarese C; Caliò A; Munari E; Cima L; Porcaro AB; Novella G; Artibani W; Sava T; Eccher A; Ghimenton C; Bertoldo F; Scarpa A; Sperandio N; Porta C; Bronte V; Chilosi M; Bogina G; Zamboni G; Tortora G; Samaratunga H; Martignoni G; Brunelli M
Target Oncol; 2016 Jun; 11(3):345-51. PubMed ID: 26566945
[TBL] [Abstract][Full Text] [Related]
19. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
20. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
